Component

Chamomile extract in the 2016 anxiety-relapse trial

Chamomile extract in the 2016 anxiety-relapse trial

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Chamomile continuation did not significantly reduce the primary relapse outcome: 7/46 versus 12/47, hazard ratio 0.52, 95% CI 0.20–1.33, P=0.16.

    Chamomile extract in the 2016 anxiety-relapse trial → Anxiety relapse in the 2016 chamomile continuation trial Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    experimental_contrast
    {"intervention": "Continued chamomile extract", "comparator": "Placebo after initial response", "endpoint": "Chamomile continuation did not significantly reduce the primary relapse outcome: 7/46 versus 12/47, hazard ratio 0.52, 95% CI 0.20–1.33, P=0.16.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    93 responders randomized after a 12-week open-label phase; 1500 mg extract/day, 26-week continuation.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    Chamomile continuation did not significantly reduce the primary relapse outcome: 7/46 versus 12/47, hazard ratio 0.52, 95% CI 0.20–1.33, P=0.16.
    primary_references
    Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. | https://pubmed.ncbi.nlm.nih.gov/27912875/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5646235/ | https://doi.org/10.1016/j.phymed.2016.10.012
    source_locator
    Reviewed reference api-chamomile-relapse-null; Responder-enriched design and imprecision limit inference. Secondary symptom scores improved, but they do not replace the null primary outcome.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 820–826

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · 93 responders randomized after a 12-week open-label phase; 1500 mg extract/day, 26-week continuation. · Recorded from source · Recorded from source

    ### api-chamomile-relapse-null Chamomile continuation did not significantly reduce the primary relapse outcome: 7/46 versus 12/47, hazard ratio 0.52, 95% CI 0.20–1.33, P=0.16. Responder-enriched design and imprecision limit inference. Secondary symptom scores improved, but they do not replace the null primary outcome. Model and exposure: 93 responders randomized after a 12-week open-label phase; 1500 mg extract/day, 26-week continuation. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. | 2016 | https://pubmed.ncbi.nlm.nih.gov/27912875/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5646235/ | https://doi.org/10.1016/j.phymed.2016.10.012 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    Complete structured claim and evidence

  2. The continuation trial reported better secondary anxiety-symptom scores with chamomile, P=0.0032.

    Chamomile extract in the 2016 anxiety-relapse trial → Secondary anxiety symptoms in the 2016 chamomile trial Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    experimental_contrast
    {"intervention": "Continued extract", "comparator": "Placebo", "endpoint": "The continuation trial reported better secondary anxiety-symptom scores with chamomile, P=0.0032.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Same responder-enriched study.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    The continuation trial reported better secondary anxiety-symptom scores with chamomile, P=0.0032.
    primary_references
    Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. | https://pubmed.ncbi.nlm.nih.gov/27912875/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5646235/ | https://doi.org/10.1016/j.phymed.2016.10.012
    source_locator
    Reviewed reference api-chamomile-symptoms; Kept alongside the nonsignificant primary relapse result, not substituted for it.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 828–834

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Same responder-enriched study. · Recorded from source · Recorded from source

    ### api-chamomile-symptoms The continuation trial reported better secondary anxiety-symptom scores with chamomile, P=0.0032. Kept alongside the nonsignificant primary relapse result, not substituted for it. Model and exposure: Same responder-enriched study. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. | 2016 | https://pubmed.ncbi.nlm.nih.gov/27912875/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5646235/ | https://doi.org/10.1016/j.phymed.2016.10.012 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.